Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Centre Leon Berard currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This specific matter is assigned to 1 distinct examiner, SABILA, MERCY HELLEN, who also serves as the busiest examiner for the portfolio. The prosecution activity is concentrated within 1 distinct art unit, reflecting a focused technical scope for the company patent portfolio.
Practitioners should note that with 1 pending office action and 1 distinct examiner, the current prosecution strategy is highly centralized. Because the busiest examiner handles the 1 busiest examiner pending matter, the outcome of this specific interaction will dictate the immediate progress of the company intellectual property. The reliance on 1 distinct art unit suggests that the pending application falls within a specialized regulatory or examination group within the Biotechnology & Pharmaceuticals sector.
This singular focus allows the legal team to concentrate their resources on the specific examination style of SABILA, MERCY HELLEN. However, the lack of diversity in examiners or art units means that any procedural delays will affect the entire active portfolio. Navigating the active matter requires a precise response tailored to the technical standards of the assigned art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIM, DAVID M. | 1 | 58.3% | +58.3% |
| SABILA, MERCY HELLEN | 1 | 57.0% | +46.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17760024 | METHODS OF TREATMENT OF CANCER DISEASE BY TARGETING AN EPIGENETIC FACTOR | SABILA, MERCY HELLEN | 126d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17760024 | METHODS OF TREATMENT OF CANCER DISEASE BY TARGETING AN EPIGENETIC FACTOR | SABILA, MERCY HELLEN | 126d overdue |
| 18699257 | Benzimidazole derivatives for use in the treatment or prevention of a histiocytosis or a craniopharyngioma | SHIM, DAVID M. | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18699257 | Benzimidazole derivatives for use in the treatment or prevention of a histiocytosis or a craniopharyngioma | SHIM, DAVID M. | 1626 | §103§112DP | Non-Final OA | — | Pending | Apr 05, 2024 |
| 17760024 | METHODS OF TREATMENT OF CANCER DISEASE BY TARGETING AN EPIGENETIC FACTOR | SABILA, MERCY HELLEN | 1654 | §103§112 | Non-Final OA | 126d overdue | Pending | Aug 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial